Clinical Trials and Research

Background: Acoramidis is a novel, potent, investigational, transthyretin (TTR) stabilizer under development for the treatment of TTR amyloidosis that results in…

DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics…

In its native tetrameric form, transthyretin (TTR) protein, which is primarily produced in the liver, serves as a carrier for thyroxin and retinol binding protein […

This study is testing a potential new medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis.The study will look at if this medicine can…

This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe this medicine is in the long…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 30, 2024-- Alnylam Pharmaceuticals, Inc.external link, opens in a new tab (Nasdaq: ALNY), the leading RNAi therapeutics…

In Canada, an active 66-year-old man with no signs or symptoms of heart failure is diagnosed with atrial fibrillation after experiencing several weeks of…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 24, 2024-- Alnylam Pharmaceuticals, Inc.external link, opens in a new tab (Nasdaq: ALNY), the leading RNAi therapeutics…

OverviewISAP examines the effects of oral semaglutide, a glucagon-like protein-1 receptor agonist used for diabetes, on the build-up of proteins in the brain…

A recently granted patent (Publication Number: US11912759B2) discloses an antibody designed to bind to human transthyretin. The antibody comprises specific amino…